| 1 | miR-145抑制c-Myc基因表达对鼻咽癌细胞增殖的影响显示文摘目的:探究miR-145影响鼻咽癌细胞增殖可能的机制。方法:采用Real-time PCR法检测鼻咽癌细胞株CNE-1、CNE-2、CNE-2Z和鼻咽部永生化上皮细胞株NP69中miR-145和c-Myc的mRNA表达水平,Western blotting法检测c-Myc的蛋白表达水平,双萤光素酶报告基因实验检测miR-145与基因c-Myc的关系。分别将miR-Negative control、miR-145 mimics和siNC、si-c-Myc转染进入CNE-1细胞,采用Real-time PCR及Western blotting法检测转染效果,CCK-8法检测转染后细胞的增殖情况,以及碘化丙啶(IP)染色流式细胞术检测细胞周期情况。结果:miR-145在鼻咽癌细胞系中明显低表达。转染miR-145后明显抑制CNE-1细胞的增殖[3 d:(1.03±0.02)vs(1.21±0.02),P<0.05];[4 d:(1.79±0.02)vs(2.09±0.07),P<0.01]和导致G1期阻滞[(79.57±1.47)%vs(69.98±1.16)%,P<0.05]。miR-145可以直接作用于c-Myc的3’UTR区域,抑制c-Myc的转录和表达。c-Myc下调可明显抑制CNE-1细胞的增殖[3 d:(0.80±0.02)vs(1.02±0.01),P<0.01];[4 d:(1.68±0.4)vs(1.92±0.07),P<0.01],并致G1期阻滞[(63.73±1.81)%vs(54.10±2.26)%,P<0.05]。结论:miR-145通过靶向作用于c-Myc的3’UTR区来抑制鼻咽癌细胞的增殖,对更深入探索鼻咽癌的诊断和治疗有着重要意义。 | 陈红兵 黄海平 刘霞 雷哲 刘济生 | 2015 | 中国肿瘤生物治疗杂志2015，22，5： | 5 |
| 2 | Relationships between cell cycle pathway gene polymorphisms and risk of hepatocellular carcinoma显示文摘AIM: To investigate the associations between the polymorphisms of cell cycle pathway genes and the risk of hepatocellular carcinoma(HCC). METHODS: We enrolled 1127 cases newly diagnosed with HCC from the Tumor Hospital of Guangxi Medical University and 1200 non-tumor patients from the First Affiliated Hospital of Guangxi Medical University. General demographic characteristics, behavioral information, and hematological indices were collected by unified questionnaires. Genomic DNA was isolatedfrom peripheral venous blood using Phenol-Chloroform. The genotyping was performed using the Sequenom Mass ARRAY i PLEX genotyping method. The association between genetic polymorphisms and risk of HCC was shown by P-value and the odd ratio(OR) with 95% confidence interval(CI) using the unconditional logistic regression after adjusting for age, sex, nationality, smoking, drinking, family history of HCC, and hepatitis B virus(HBV) infection. Moreover, stratified analysis was conducted on the basis of the status of HBV infection, smoking, and alcohol drinking.RESULTS: The HCC risk was lower in patients with the MCM4 rs2305952 CC(OR = 0.22, 95%CI: 0.08-0.63, P = 0.01) and with the CHEK1 rs515255 TC, TT, TC/TT(OR = 0.73, 95%CI: 0.56-0.96, P = 0.02; OR = 0.67, 95%CI: 0.46-0.97, P = 0.04; OR = 0.72, 95%CI: 0.56-0.92, P = 0.01, respectively). Conversely, the HCC risk was higher in patients with the KAT2 B rs17006625 GG(OR = 1.64, 95%CI: 1.01-2.64, P = 0.04). In addition, the risk was markedly lower for those who were carriers of MCM4 rs2305952 CC and were also HBs Ag-positive and non-drinking and nonsmoking(P < 0.05, respectively) and for those who were carriers of CHEK1 rs515255 TC, TT, TC/TT and were also HBs Ag-negative and non-drinking(P < 0.05, respectively). Moreover, the risk was higher for those who were carriers of KAT2 B rs17006625 GG and were also HBs Ag-negative(P < 0.05).CONCLUSION: Of 12 cell cycle pathway genes, MCM4, CHEK1 and KAT2 B polymorphisms may be associated with the risk of HCC. | Yue-Li Nan Yan-Ling Hu Zhi-Ke Liu Fang-Fang Duan Yang Xu Shu Li Ting Li Da-Fang Chen Xiao-Yun Zeng | 2016 | World Journal of Gastroenterology2016，22，24： | 2 |
您所在的机构暂未开通此部分的功能，请联系管理员